Vienna, Austria

Andrea Dolischka

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 5.5

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2013-2015

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Andrea Dolischka: Innovator in Vaccine Development

Introduction

Andrea Dolischka is a prominent inventor based in Vienna, Austria. She has made significant contributions to the field of medical research, particularly in vaccine development. With a total of two patents to her name, Dolischka is recognized for her innovative approaches to addressing critical health issues.

Latest Patents

Dolischka's latest patents include a vaccine comprising a peptide bound to a pharmaceutically acceptable carrier. This peptide has a specific amino acid sequence that is crucial for its effectiveness. Additionally, she has developed compounds for treating beta-amyloidoses. This invention relates to the use of mimotopes in the treatment of diseases associated with beta-amyloid formation and aggregation, including Alzheimer's disease. The mimotopes are designed to induce the in vivo formation of antibodies directed to various beta-amyloid sequences.

Career Highlights

Dolischka is currently associated with Affiris AG, a company known for its innovative approaches in the pharmaceutical industry. Her work at Affiris AG has allowed her to focus on groundbreaking research that has the potential to impact the treatment of serious diseases.

Collaborations

Some of her notable coworkers include Frank Mattner and Markus Mandler, who contribute to the collaborative environment that fosters innovation and research excellence.

Conclusion

Andrea Dolischka stands out as a key figure in the field of vaccine development, with her patents reflecting her commitment to advancing medical science. Her work continues to inspire future innovations in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…